Literature DB >> 25545125

Pharmacology of Src family kinases and therapeutic implications of their modulators.

Amit Kumar1, Amteshwar S Jaggi, Nirmal Singh.   

Abstract

Src family kinases (SFKs), the largest family of nonreceptor tyrosine kinases, include 10 members. Src was the first gene product discovered to have intrinsic protein tyrosine kinase activity. Src is widely expressed in many cell types and can have different locations within a cell; the subcellular location of Src can affect its function. Src can associate with cellular membranes, such as the plasma membrane, the perinuclear membrane, and the endosomal membrane. SFKs actions on mammalian cells are pleiotropic and include effect on cell morphology, adhesion, migration, invasion, proliferation, differentiation, and survival. SFKs at one end have been documented to play some important physiological functions; on the other end, they have been described in the pathophysiology of some disorders. In this review article, an exhaustive attempt has been made to unearth pharmacology of SFKs and therapeutic implications of SFKs modulators.
© 2014 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  Src kinase; cancer; epilepsy; ischemia; memory

Mesh:

Substances:

Year:  2015        PMID: 25545125     DOI: 10.1111/fcp.12097

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  11 in total

Review 1.  Manipulation of Focal Adhesion Signaling by Pathogenic Microbes.

Authors:  Korinn N Murphy; Amanda J Brinkworth
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

2.  Deficiency of the Src homology phosphatase 2 in podocytes is associated with renoprotective effects in mice under hyperglycemia.

Authors:  Ming-Fo Hsu; Yoshihiro Ito; Maryam Afkarian; Fawaz G Haj
Journal:  Cell Mol Life Sci       Date:  2022-09-14       Impact factor: 9.207

Review 3.  Behind the scenes: Are latent memories supported by calcium independent plasticity?

Authors:  Rachel E Keith; Richard H Ogoe; Theodore C Dumas
Journal:  Hippocampus       Date:  2021-04-27       Impact factor: 3.899

4.  Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.

Authors:  Marco Perez; Antonio Lucena-Cacace; Luis Miguel Marín-Gómez; Javier Padillo-Ruiz; Maria Jose Robles-Frias; Carmen Saez; Rocio Garcia-Carbonero; Amancio Carnero
Journal:  Oncotarget       Date:  2016-05-31

5.  Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.

Authors:  Alejandra M Petrilli; Jeanine Garcia; Marga Bott; Stephani Klingeman Plati; Christine T Dinh; Olena R Bracho; Denise Yan; Bing Zou; Rahul Mittal; Fred F Telischi; Xue-Zhong Liu; Long-Sheng Chang; D Bradley Welling; Alicja J Copik; Cristina Fernández-Valle
Journal:  Oncotarget       Date:  2017-05-09

6.  Disturbances in PP2A methylation and one-carbon metabolism compromise Fyn distribution, neuritogenesis and APP regulation.

Authors:  Goce Taleski; Diana Schuhmacher; Henry Su; Jean-Marie Sontag; Estelle Sontag
Journal:  J Biol Chem       Date:  2020-12-30       Impact factor: 5.157

Review 7.  Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold.

Authors:  Daniel J Baillache; Asier Unciti-Broceta
Journal:  RSC Med Chem       Date:  2020-09-08

Review 8.  Signaling Pathways That Regulate Normal and Aberrant Red Blood Cell Development.

Authors:  Mark C Wilkes; Aya Shibuya; Kathleen M Sakamoto
Journal:  Genes (Basel)       Date:  2021-10-19       Impact factor: 4.141

9.  SPOCK1 Promotes the Development of Hepatocellular Carcinoma.

Authors:  Lóránd Váncza; Katalin Karászi; Bálint Péterfia; Lilla Turiák; Katalin Dezső; Anna Sebestyén; Andrea Reszegi; Gábor Petővári; András Kiss; Zsuzsanna Schaff; Kornélia Baghy; Ilona Kovalszky
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

Review 10.  Caveolin-1 and MLRs: A potential target for neuronal growth and neuroplasticity after ischemic stroke.

Authors:  Wei Zhong; Qianyi Huang; Liuwang Zeng; Zhiping Hu; Xiangqi Tang
Journal:  Int J Med Sci       Date:  2019-10-15       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.